An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Peking Union Medical College Hospital
300 participants
May 1, 2024
INTERVENTIONAL
Conditions
Summary
This is a multicenter, non-randomized, umbrella, open-label phase II clinical study, aiming to observe and evaluate, as well as explore the efficacy and safety of precision targeted therapy based on NGS technology for IDH1-mutated patients, specifically the combination of ivosidenib with multi-target tyrosine kinase inhibitors represented by lenvatinib or PD-1/PD-L1 in advanced biliary tract cancer patients who have failed systemic chemotherapy.
Eligibility
Inclusion Criteria10
- Voluntary Participation: Signed informed consent.
- Genetic Mutation: Presence of an IDH1 mutation confirmed by genetic testing.
- Disease Status：
- Newly diagnosed, untreated advanced/metastatic disease; OR
- Recurrence >6 months after curative-intent surgery (with or without adjuvant therapy).
- Measurable Disease: At least one measurable lesion per RECIST 1.1.
- Performance Status: ECOG performance status of 0 or 1.
- Life Expectancy： ≥3 months.
- Organ Function: Adequate hematological, hepatic, and renal function.
- Contraception: Use of highly effective contraception for women of childbearing potential and men.
Exclusion Criteria15
- Prior Treatment: Previous treatment with Ivosidenib.
- Cancer Type: Ampulla of Vater cancer.
- Pregnancy： Pregnant or breastfeeding women.
- Allergy: Known hypersensitivity to any component of the study drugs.
- Recent Therapy: Local anti-tumor therapy or major surgery within 4 weeks prior to initiation.
- Medical Conditions:
- Uncontrolled hypertension.
- Significant cardiovascular disease.
- Active or untreated CNS metastases.
- Active autoimmune disease.
- Uncontrolled active infection (e.g., HBV, HCV, HIV).
- Significant bleeding tendency or history.
- Severe non-healing wounds.
- History of organ transplantation.
- Concurrent Participation: Participation in another interventional clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral, selective, small-molecule inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. Administered at a dose of 500 mg, taken orally once daily. This is the core investigational drug in all study arms.
Oral, multi-targeted tyrosine kinase inhibitor. Administered at a weight-based dose (8 mg for body weight \<60 kg or 12 mg for body weight ≥60 kg), taken orally once daily. Used in combination arms.
Intravenous immune checkpoint inhibitor. Specific agent (e.g., Pembrolizumab, Durvalumab, Toripalimab, or Tislelizumab) may be chosen based on local availability and patient access. Administered at standard doses (e.g., 200 mg, 1500 mg, or 240 mg) via IV infusion every three weeks. Used in combination arms.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07282262